Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes

Fig. 1

The effects of dapagliflozin on the metabolic characteristics in ZDF rats. a Changes in body weight. b Random blood glucose. c, d Diastolic and systolic blood pressure. e, f Intraperitoneal glucose tolerance tests were performed, and the area under the curve was calculated. g–i The serum lipid profile of all rats. The data are presented as the mean ± SD. n = 8 per group. *P < 0.05, **P < 0.01 vs. Lean; #P < 0.05, ##P < 0.01 vs. ZDF

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us